New Directions In STD Treatment - University of Hawaii
New Directions In STD Treatment - University of Hawaii New Directions In STD Treatment - University of Hawaii
Indications for More Frequent Screening in MSM � Increased prevalence of STIs in area or patient population � Symptoms or recent history of any STI in patient or partner � Risky sexual behavior � Multiple or anonymous partners � Substance abuse especially methamphetamine � Risky sexual behavior in partner � If any of the above, then screen q 3-6 months MMWR 2003 52: RR 12
Prevalence of rectal chlamydia and gonorrhea by symptom status among MSM – San Francisco, 2003 35% 30% 25% 20% 15% 10% 5% 0% 20.7% 7.6% 29.8% 6.1% n=213 n=3579 n=212 n=3613 Chalmydia Gonorrhea Symptomatic Asymptomatic Kent, CK et al. ISSTDR, July 2005
- Page 1 and 2: New Directions in STD Treatment: Hi
- Page 3 and 4: CDC 2006 STD Treatment Guidelines D
- Page 5 and 6: Challenging Management Dilemmas in
- Page 7 and 8: Sexual History Taking: The 5 P’s
- Page 9 and 10: Recommend Nucleic Acid Amplificatio
- Page 11 and 12: Percent Screened Estimated Chlamydi
- Page 13: STD Screening for MSM STD Site Type
- Page 17 and 18: Prevalence of pharyngeal chlamydia
- Page 19 and 20: C. trachomatis NAAT Testing …not
- Page 21 and 22: Chlamydia Treatment in Pregnancy Re
- Page 23 and 24: Percent 16 14 12 10 Infection Durin
- Page 25 and 26: Provider Barriers to PDPT, CA 2002
- Page 27 and 28: Gonorrhea Screening in Females �
- Page 29 and 30: Percent of Neisseria gonorrhoeae Is
- Page 31 and 32: Gonorrhea Treatment of Urogenital I
- Page 33 and 34: Lymphogranuloma Venereum (LGV) C. t
- Page 35 and 36: LGV Proctocolitis: Serologic Diagno
- Page 37 and 38: Phil and the Penis on the Go
- Page 39 and 40: The Three “R”s of Syphilis �
- Page 41 and 42: Latent Syphilis � No clinical man
- Page 43 and 44: Syphilis EIA Tests �Treponemal te
- Page 45 and 46: Criteria for CSF Examination � Ne
- Page 47 and 48: Syphilis Resistant to Azithromycin!
- Page 51 and 52: HSV Issues � Role of type-specifi
- Page 53 and 54: Rates of Transmission of HSV-2 to S
- Page 55 and 56: Genital Herpes - Treatment Issues
- Page 57 and 58: HPV Issues � Clarify uses of HPV
- Page 59 and 60: Issues Regarding Anal Cancer Screen
- Page 61 and 62: Cervicitis - Diagnostic Issues �
- Page 63 and 64: Pelvic Inflammatory Disease Issues
<strong>In</strong>dications for More Frequent<br />
Screening in MSM<br />
� <strong>In</strong>creased prevalence <strong>of</strong> STIs in area or patient<br />
population<br />
� Symptoms or recent history <strong>of</strong> any STI in patient<br />
or partner<br />
� Risky sexual behavior<br />
� Multiple or anonymous partners<br />
� Substance abuse especially methamphetamine<br />
� Risky sexual behavior in partner<br />
� If any <strong>of</strong> the above, then screen q 3-6 months<br />
MMWR 2003 52: RR 12
Change language